Gilead Sciences EVP Unloads $5,679,900 in Stock (GILD)
Gilead Sciences (NASDAQ:GILD) EVP Norbert Bischofberger unloaded 90,000 shares of the stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $63.11, for a total transaction of $5,679,900.00. Following the sale, the executive vice president now directly owns 2,159,643 shares in the company. The transaction was disclosed in a filing with the SEC, which is available at this link.
A number of research firms have recently commented on GILD. Analysts at TheStreet reiterated a “buy” rating on shares of Gilead Sciences (NASDAQ:GILD) in a research note to investors on Tuesday, September 3rd.
Five investment analysts have rated the stock with a hold rating and twenty-two have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $67.87.
Gilead Sciences (NASDAQ:GILD) traded up 2.54% on Wednesday, hitting $64.28. The stock had a trading volume of 7,918,053 shares. Gilead Sciences has a one year low of $32.07 and a one year high of $64.21. The stock’s 50-day moving average is $60.45 and its 200-day moving average is $54.03. The company has a market cap of $98.389 billion and a P/E ratio of 35.08.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, July 25th. The company reported $0.50 EPS for the quarter, meeting the Thomson Reuters consensus estimate of $0.50. The company had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.66 billion. During the same quarter in the prior year, the company posted $0.99 earnings per share. The company’s quarterly revenue was up 14.5% on a year-over-year basis. On average, analysts predict that Gilead Sciences will post $1.97 earnings per share for the current fiscal year.
Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.